脂质体长春新碱联合Hyper-CMAD方案治疗初诊急性淋巴细胞白血病的2期研究
结果显示97%患者达完全缓解,5年完全缓解持续率和生存率分别为73%和61%,3/4级周围神经病变发生率为16%。
要点
- 脂质体长春新碱联合Hyper-CMAD在初诊ALL中显示高缓解率和生存率。
- 3/4级周围神经病变发生率为16%,安全性可控。
- Ph阳性ALL患者中95%达主要分子学缓解,70%达完全分子学缓解。
核心结论
- 脂质体长春新碱联合Hyper-CMAD方案在初诊ALL中安全且显示高缓解率和生存率。
主要发现
- 30例(97%)达完全缓解,26例异常核型患者均达完全细胞遗传学缓解。
- 27/30例(90%)通过多色流式细胞术达微小残留病阴性。
- 20例可评估Ph阳性患者中,19例(95%)达主要分子学缓解,14例(70%)达完全分子学缓解。
- 3/4级周围神经病变见于5例(16%),任何级别周围神经病变见于21例(68%)。
- 中位随访59个月,21例(68%)存活,5年完全缓解持续率和生存率分别为73%和61%。
关键数值与推荐
- 微小残留病阴性率90%(27/30),主要分子学缓解率95%(19/20),完全分子学缓解率70%(14/20)。
- 5年完全缓解持续率73%,5年生存率61%。
临床怎么用
- 脂质体长春新碱可作为初诊ALL联合化疗中普通长春新碱的替代选择,需关注周围神经病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liposomal vincristine is designed to reduce neurotoxicity and increase dose intensity delivery, and has been approved as salvage therapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Our aim was to evaluate the response rate, toxicities, and outcome of adults with newly diagnosed ALL who received liposomal vincristine, rather than regular vincristine in combination with intensive chemotherapy (Hyper-CMAD). In a single-center, phase 2 study, patients ≥18 years with newly-diagnosed B-cell ALL were eligible to receive hyper-CMAD alternating with high-dose methotrexate and cytarabine. Rituximab was administered in CD20 positive ALL. Tyrosine kinase inhibitors (imatinib or dasatinib) were added in Philadelphia chromosome-positive (Ph-positive) ALL. Thirty-one patients were enrolled, median follow-up of 59 months (0.3-70). Thirteen patients (42%) had CD20 positive ALL, and 21 (68%) had Ph-positive ALL. Thirty (97%) achieved complete remission (CR). All 26 patients with abnormal karyotype achieved complete cytogenetic response (CCyR), and 27/30 (90%) achieved negative minimal residual disease status by multicolor flow cytometry. Of 20 evaluable Ph-positive ALL patients, major molecular response (MMR) was achieved in 19 patients (95%); complete molecular response (CMR) in 14 (70%). Grade 3/4 peripheral neuropathy was observed in five (16%) with all grade peripheral neuropathy in 21 (68%). With a median follow-up of 59 months, 21 (68%) patients are alive. The 5-year CR duration and survival rates were 73% and 61%, respectively. Ten (32%) patients died: one, sepsis on C1D10; four, unknown; one, post-transplant complications; four, relapse. Hyper-CMAD with liposomal vincristine is safe and demonstrated high response and survival rates in newly diagnosed ALL.
引用
- Sasaki K, Kantarjian H, Wierda W, et al. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020. PMID: 32170867. doi:10.1002/ajh.25784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。